Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant

Clinical Trial Description

Randomized ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

See also
Status	Clinical Trial	Phase
Completed	`NCT00491517` - Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	Phase 2
Recruiting	`NCT05286632` - KidneYou - Innovative Digital Therapy	N/A
Active, not recruiting	`NCT00771888` - Open-Label Extension of LOCKCYST Trial	Phase 2/Phase 3
No longer available	`NCT03717181` - Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease

See also

Status

Clinical Trial

Phase

Completed

NCT00491517 - Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety

Phase 2

Recruiting

NCT05286632 - KidneYou - Innovative Digital Therapy

N/A

Active, not recruiting

NCT00771888 - Open-Label Extension of LOCKCYST Trial

Phase 2/Phase 3

No longer available

NCT03717181 - Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT00801268
Study type	Interventional
Source	Nanjing University School of Medicine
Contact
Status	Terminated
Phase	N/A
Start date	November 2008
Completion date	November 2013

Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms